Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05575973
What this trial is testing

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
Jianfeng Zhou 55
Not applicableLooking for participantsNCT06898905
What this trial is testing

Hyperfractionated Dual Equivalent Fractionated Radiation Therapy

Who this might be right for
Diffuse Large B-Cell Lymphoma
Yale University 10
Testing effectiveness (Phase 2)Study completedNCT05322330
What this trial is testing

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University 20
Early research (Phase 1)Study completedNCT00083213
What this trial is testing

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Cancer
Regeneron Pharmaceuticals 25
Early research (Phase 1)Ended earlyNCT03558750
What this trial is testing

Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

Who this might be right for
Recurrent Central Nervous System LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Central Nervous System Lymphoma+1 more
Vanderbilt-Ingram Cancer Center 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT05283720
What this trial is testing

Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
Genmab 264
Early research (Phase 1)Study completedNCT01410513
What this trial is testing

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
Sanofi 37
Early research (Phase 1)Looking for participantsNCT06208735
What this trial is testing

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Who this might be right for
B-Cell LeukemiaNon-Hodgkin's LymphomaB-cell Acute Lymphoblastic Leukemia+5 more
British Columbia Cancer Agency 24
Early research (Phase 1)Looking for participantsNCT06047197
What this trial is testing

Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-cell Lymphoma
Beijing Yongtai Ruike Biotechnology Company Ltd 25
Testing effectiveness (Phase 2)Looking for participantsNCT06552559
What this trial is testing

Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

Who this might be right for
B-cell Lymphoma RecurrentB-cell Lymphoma RefractoryCNS Metastases
Samsung Medical Center 37
Large-scale testing (Phase 3)Active Not RecruitingNCT05578976
What this trial is testing

Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Genmab 900
Testing effectiveness (Phase 2)Study completedNCT02445248
What this trial is testing

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Who this might be right for
Diffuse Large B-cell Lymphoma (DLBCL)
Novartis Pharmaceuticals 115
Very early researchStudy completedNCT02405078
What this trial is testing

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center 35
Testing effectiveness (Phase 2)WithdrawnNCT04285268
What this trial is testing

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell Lymphoma+4 more
Rutgers, The State University of New Jersey
Testing effectiveness (Phase 2)Study completedNCT05068440
What this trial is testing

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Who this might be right for
Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-cell Lymphoma
BeiGene 65
Early research (Phase 1)Ended earlyNCT00521638
What this trial is testing

Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, B-Cell
Wyeth is now a wholly owned subsidiary of Pfizer 120
Early research (Phase 1)Ended earlyNCT02978235
What this trial is testing

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Who this might be right for
Multiple MyelomaNonHodgkin Lymphoma
Taiho Oncology, Inc. 11
Testing effectiveness (Phase 2)Looking for participantsNCT07538635
What this trial is testing

CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.

Who this might be right for
High-risk R/R LBCL
Zhejiang Cancer Hospital 20
Testing effectiveness (Phase 2)UnknownNCT02758925
What this trial is testing

CyBeR Association in Relapsed/Refractory DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
University Hospital, Caen 78
Testing effectiveness (Phase 2)Active Not RecruitingNCT03162536
What this trial is testing

Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Who this might be right for
Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 190
Next Page